Not yet taking people in ItalyPhase 4
Tailored antiplatelet drugs to prevent another stroke in non-cardioembolic ischemic stroke
Tests tailored antiplatelet drug choices against usual care in adults after ischemic stroke.
Key facts
- Who runs it
- Azienda Unita Sanitaria Locale Di Bologna
- Where
- Bologna, Cesena, and Modena, ItalySee the 3 sites
- Trial code
- Registry title
- Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 1,506 people, planned
- Started
- 16 Feb 2026
- Expected to end
- 31 Aug 2029
- Type of study
- Interventional
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who recently had an ischemic stroke not caused by the heart and who are starting or continuing antiplatelet medicine to prevent another stroke.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Ischemic stroke not caused by the heart (non-cardioembolic), within the previous 14 days
- Earlier treatment
- Starting or continuing single or double antiplatelet therapy after the stroke
Main reasons for not taking part
- Allergy to aspirin, clopidogrel or ticlopidine
- Need for blood thinners (anticoagulants) for any reason
- Active or past stomach ulcer or bleeding, including bleeding in the brain
- Bleeding or clotting disorders such as hemophilia or low platelets
- Pregnancy, breastfeeding, or no accepted contraception for women who can have children
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Aged ≥18 years old
- Males and females
- Non-cardioembolic ischemic stroke within the previous 14 days
- Starting/prosecuting secondary prevention with single or double anti-platelet therapy after the index stroke
- Written informed consent (informed consent can be obtained on incapacitated patients in accordance with national legislation (versions “ex art. 82” of informed consent to study participation and data treatment consent)
Who cannot take part
- Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis
- Concurrent need for anticoagulation for any indication
- Contraindication to study drugs
- Indications to perform carotid revascularization surgery
- Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage
- Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipient
- Severe renal impairment
- Uncontrolled severe cardiac failure
- History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs
- Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia
- Severe hepatic impairment
- Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide)
Where in Italy
- Azienda Unita Sanitaria Locale Di BolognaBologna, ItalyNot yet recruiting
- Azienda Unita Sanitaria Locale Della RomagnaCesena, ItalyNot yet recruiting
- Azienda Ospedaliero - Universitaria di ModenaModena, ItalyNot yet recruiting
About the trial
What the trial wants to find out
To demonstrate that a tailored prescription of antiplatelet drugs can cut the rate of 12-month major cardiovascular events compared to usual care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
- Plain-language title
- Tailored antiplatelet drugs to prevent another stroke in non-cardioembolic ischemic strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 April 2026